Literature DB >> 1868598

Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases.

R Molina1, X Filella, J Bruix, P Mengual, J Bosch, X Calvet, J Jo, A M Ballesta.   

Abstract

Serum concentrations of cancer antigen 125 (CA 125) were determined for 373 patients with various liver diseases: 57 with acute hepatitis, 57 with chronic hepatitis, 244 with liver cirrhosis (86 compensated and 158 decompensated), and 15 with primary liver cancer. The antigen was measured simultaneously in the serum and ascitic fluid of 46 of the patients with liver cirrhosis and sequentially in the serum and ascitic fluid of another 25 cirrhotics treated with paracentesis and (or) diuretics. Abnormal results for CA 125 were detected in sera from 4% of the patients with acute or chronic hepatitis, 60% of the patients with liver cirrhosis, and 67% of the patients with primary liver cancer. The main factor associated with abnormal serum concentrations of this antigen was the presence of ascites, with pathological CA 125 values in 94% of patients with ascites without jaundice (mean 566 +/- 528 arb. units/mL), compared with only 40% of patients with jaundice and without ascites (mean 40.1 +/- 28.5 arb. units/mL) (P less than 0.001). High concentrations of CA 125 were mainly associated with spontaneous bacterial peritonitis. The serum concentration of CA 125 decreased after treatment with paracentesis, but increased in patients treated with diuretics rather than paracentesis. The release of this antigen in liver cirrhosis appears to be independent of the liver disorder and, rather, results from peritoneal synthesis of this antigen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868598

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  17 in total

1.  Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site.

Authors:  Rafael Molina; Xavier Bosch; Josep M Auge; Xavier Filella; José M Escudero; Víctor Molina; Manel Solé; Alfonso López-Soto
Journal:  Tumour Biol       Date:  2011-12-09

2.  Marked decrease of serum Ca 125 levels after Denver shunt placement in a patient with cirrhosis and refractory ascites.

Authors:  L Leggio; L Abenavoli; C D'Angelo; A Ferrulli; L Vonghia; A Mirijello; R Barbarino; T De Michele; C Zuppi; D Gui; G L Rapaccini; G Gasbarrini; G Addolorato
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

3.  HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.

Authors:  Rafael Molina; Jose M Escudero; Jose M Augé; Xavier Filella; Laura Foj; Aureli Torné; Jose Lejarcegui; Jaume Pahisa
Journal:  Tumour Biol       Date:  2011-08-24

4.  Screening for ovarian cancer. Other chronic diseases affect serum marker.

Authors:  P Tambyah; I Yap; W C Lye
Journal:  BMJ       Date:  1993-06-19

5.  Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients.

Authors:  M M Uttenreuther-Fischer; H Feistel; F Wolf; W Jäger
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

6.  HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.

Authors:  Blanca Ortiz-Muñoz; Eduardo Aznar-Oroval; Ana García García; Amparo Covisa Peris; Pilar Perez Ballestero; Marina Sanchez Yepes; Tomás Garcia Lozano; Carmen Illueca Ballester; Enrique García Garcia
Journal:  Tumour Biol       Date:  2014-04-27

7.  The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.

Authors:  Maximilian Schöniger-Hekele; Christian Müller
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

8.  CA 125 secretion by peritoneal mesothelial cells.

Authors:  A M Zeillemaker; H A Verbrugh; A A Hoynck van Papendrecht; P Leguit
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

9.  Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis.

Authors:  Yukinori Koyama; Ping Wang; Shuang Liang; Keiko Iwaisako; Xiao Liu; Jun Xu; Mingjun Zhang; Mengxi Sun; Min Cong; Daniel Karin; Kojiro Taura; Chris Benner; Sven Heinz; Tapan Bera; David A Brenner; Tatiana Kisseleva
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

10.  Validity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian Cancer.

Authors:  Khawla Al-Musalhi; Manal Al-Kindi; Fatma Ramadhan; Thuraya Al-Rawahi; Khalsa Al-Hatali; Waad-Allah Mula-Abed
Journal:  Oman Med J       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.